GlassScriptPhysician profile
Bryan A Kelly
NPI 1750678660
$7,083.95
in general payments reported to CMS, 2019-2025
7 companies · $4,713 in 2025
The $4,713 reported for 2025 was more than what 88% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,117 · 2021: $71.80 · 2022: $190 · 2023: $484 · 2024: $509 · 2025: $4,713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,300 · Food and Beverage: $1,999 · Travel and Lodging: $330 · Education: $77.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,300.00 |
| Food and Beverage | $1,998.98 |
| Travel and Lodging | $329.85 |
| Education | $77.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $4,333.62 | 2019-2025 | Tyvaso, Remodulin, Orenitram |
| Bayer Healthcare Pharmaceuticals INC. | $1,338.92 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $497.05 | 2024-2025 | Uptravi, Opsumit |
| Boston Scientific Corporation | $428.00 | 2023-2025 | Ekosonic |
| Merck Sharp & Dohme LLC | $316.88 | 2024-2025 | Winrevair |
| Astrazeneca Pharmaceuticals LP | $129.39 | 2023 | |
| Edwards Lifesciences Corporation | $40.09 | 2023 | Hemosphere |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.